List of Excipients in API selumetinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing selumetinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | KOSELUGO | selumetinib | 0310-0610 | AMMONIA | 2028-09-10 |
| AstraZeneca Pharmaceuticals LP | KOSELUGO | selumetinib | 0310-0610 | BUTYL ALCOHOL | 2028-09-10 |
| AstraZeneca Pharmaceuticals LP | KOSELUGO | selumetinib | 0310-0610 | CARRAGEENAN | 2028-09-10 |
| AstraZeneca Pharmaceuticals LP | KOSELUGO | selumetinib | 0310-0610 | FERROSOFERRIC OXIDE | 2028-09-10 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for selumetinib
Excipient focus: AMMONIA
selumetinib drug variants containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYL ALCOHOL
selumetinib drug variants containing BUTYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing BUTYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CARRAGEENAN
selumetinib drug variants containing CARRAGEENAN
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing CARRAGEENAN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
selumetinib drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
selumetinib drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ISOPROPYL ALCOHOL
selumetinib drug variants containing ISOPROPYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing ISOPROPYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POTASSIUM CHLORIDE
selumetinib drug variants containing POTASSIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing POTASSIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
selumetinib drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
selumetinib drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
selumetinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: VITAMIN E POLYETHYLENE GLYCOL SUCCINATE
selumetinib drug variants containing VITAMIN E POLYETHYLENE GLYCOL SUCCINATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing VITAMIN E POLYETHYLENE GLYCOL SUCCINATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
selumetinib drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | selumetinib | 0310-0610 |
| >Company | >Ingredient | >NDC |
selumetinib drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch